Skip to main content Accessibility help
  • Print publication year: 2015
  • Online publication date: February 2015

38 - Late-onset ovarian hyperstimulation syndrome (OHSS)


1. Vlahos NF, Gregoriou O. Prevention and management of ovarian hyperstimulation syndrome. Ann N Y Acad Sci 2006; 1092: 247–64.
2. Goldsman MP, Pedram A, Dominguez CE, Ciuffardi I, Levin E, Asch RH. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril 1995; 63(2): 268–72.
3. Levin ER, Rosen GF, Cassidenti DL, Yee B, Meldrum D, Wisot A et al. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest 1998; 102(11):1978–85.
4. Damewood MD, Shen W, Zacur HA, Schlaff WD, Rock JA, Wallach EE. Disappearance of exogenously administered human chorionic gonadotropin. Fertil Steril 1989; 52(3): 398–400.
5. Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002; 87(2): 709–15.